E. De La Cuesta

Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors

A. Drilon, A. Italiano, B. Geoerger, 2021, Neuro-oncology.

CTNI-67. EFFICACY AND SAFETY OF LAROTRECTINIB IN PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS: AN EXPANDED DATASET

A. Drilon, A. Italiano, B. Geoerger, 2020 .

1955P Survival benefits of larotrectinib in an integrated dataset of patients with TRK fusion cancer

A. Drilon, J. Berlin, B. Geoerger, 2020 .

Impact of Disease Evolution on Efficacy Outcomes From Larotrectinib in Patients With Locally Advanced or Metastatic Tropomyosin Receptor Kinase Fusion–Positive Solid Tumors

C. Bokemeyer, A. Italiano, G. Vassal, 2021, JCO precision oncology.

Discovery of a rare GKAP1-NTRK2 fusion in a pediatric low-grade glioma, leading to targeted treatment with TRK-inhibitor larotrectinib

I. Øra, M. Tisell, J. Nilsson, 2021, Cancer biology & therapy.

A newborn with a large NTRK fusion positive infantile fibrosarcoma successfully treated with larotrectinib

A. Pappo, Sara Helmig, Kenneth J. Caldwell, 2020, Pediatric blood & cancer.